Lamya (Desogestrel)

Desogestrel binds to progesterone receptors in the hypothalamus and pituitary gland, inhibiting the luteinizing hormone surge that triggers ovulation. It also induces changes in the endometrium, making the uterine environment less suitable for implantation.

The dosage of Lamya is determined by the prescribing healthcare professional based on the patient’s individual needs and clinical guidelines. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Lamya is not intended for use during pregnancy and should be discontinued if pregnancy is confirmed. Safety during breastfeeding has not been fully established; the prescriber will weigh potential benefits against risks before recommending use.

To place an order, submit an enquiry on the Lamya product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lamya’s active ingredient, desogestrel, is a third‑generation progestin offering a favorable bleeding profile and lower androgenic activity compared with some older progestins. It provides comparable contraceptive efficacy while potentially reducing certain side effects such as acne.

Lamya tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, heat and direct sunlight to maintain stability and potency.

Lamya is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and should be taken as directed by the prescriber to ensure consistent contraceptive protection.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, especially in women who smoke, are over 35, or have underlying cardiovascular disease. Severe allergic reactions and liver dysfunction are also rare but important to monitor.

Lamya is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected pregnancy, or those who are breastfeeding without medical guidance. It should also be avoided in smokers over 35 years of age.